Skip to content

Bag CPAP vs Standard Oxygen Therapy in Acute Hypoxemic Respiratory Failure

Bag CPAP Versus Standard Oxygen Care for the Management of Acute Hypoxemic Respiratory Failure in Adults: A Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07460427
Acronym
BAGCPAP-R
Enrollment
250
Registered
2026-03-10
Start date
2026-04-20
Completion date
2027-03-20
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Hypoxemic Respiratory Failure

Keywords

CPAP, Randomized controlled trial, Respiratory Failure, Low resource setting

Brief summary

Acute Hypoxemic Respiratory Failure (AHRF) is one of the prevalent causes of admission around the world and is associated with high mortality in resource-limited settings. Limited access to invasive mechanical ventilation is among the contributing factors to poor outcomes. The Bag CPAP may be useful in reducing the need for intubation and therefore mortality in patients with AHRF but data are lacking. This study aims to determine whether the Bag CPAP compared to standard oxygen care, could reduce the percentage of patients with criteria for intubation in patients with AHRF. This is a prospective randomized, open-label, controlled trial in which patients presenting at the emergency room in Rwanda will be randomly assigned to receive standard oxygen therapy or Bag CPAP. The primary endpoint is the percentage of patients with criteria for intubation at day 7. Secondary endpoints include the tolerance of the Bag CPAP, overall 28-day mortality rate, mortality rate of intubated patients on mechanical ventilation at day 28, percentage of patients intubated at 28 days, ventilator-free days at day 28, interval between the initiation of treatment and the onset of intubation criteria, the interval between the time when criteria for intubation are met and intubation, organ failure-free days at day 7 and length of hospital stay.

Interventions

DEVICEBag CPAP

Bag CPAP sessions in addition to standard oxygen therapy. The Bag CPAP will be delivered continuously for the first 6 to 12 hours, then for sessions of at least 4 hours per day.

Standard oxygen therapy via nasal prongs, simple facial masks, or non-rebreather masks, depending on the need, until endotracheal intubation, death, or the presence of oxygen therapy cessation criteria

Sponsors

Prof RWABIHAMA Jean Paul
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Group oxygen vs Group oxygen+Bag CPAP

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Inclusion criteria All patients aged 18 years or older will be included in the study if they meet the following criteria: * De novo acute respiratory distress, characterized by the presence of dyspnea at rest, the use of accessory muscles for breathing, or a respiratory rate of 25 cycles per minute or more. * Hypoxemia, defined as a SpO2/FiO2 ratio less than 315 or a PaO2/FiO2 ratio less than 300 mmHg (if arterial blood gas is available) despite an oxygen therapy of 6 L/min. FiO2 will be estimated by the rule of 3% (Coudroy formula)(18,22). SpO2 should be less than 98% when assessing the SpO2/FiO2 ratio. 2.

Exclusion criteria

Patients with one of the following criteria will be excluded from the study: * Absolute contraindications to CPAP: patient's refusal, uncontrollable vomiting, upper gastrointestinal bleeding, open or sucking chest wound, pneumothorax not drained, craniofacial trauma, severe burns to the face, severe upper airway obstruction, traumatic tetraplegia at the initial stage, tracheostomy. * Moderate to massive pleural effusion not drained * Cardiac arrest, severe ventricular arrhythmias, and shock defined as the need for vasopressor support (adrenaline, noradrenaline, or dopamine) * Altered level of consciousness (GCS below 12), repetitive convulsions, or status epilepticus * Do not intubate or resuscitate order before the inclusion in the study * Refusal to participate, already included in the study, enrollment in another interventional trial on acute respiratory failure

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients with criteria for intubation at day 7Day-7Predetermined criteria for endotracheal intubation and mechanical ventilation will be considered.

Secondary

MeasureTime frameDescription
Tolerance of the Bag CPAPup to day-28Percentage of patients with facial skin abrasion and necrosis, aspiration, or sinusitis up to day 28.
Mortality rate of intubated patients on mechanical ventilationUp to day-28Invasive mechanical ventilation is defined as the delivery of positive pressure via an endotracheal or tracheostomy tube.
Ventilator-free daysup to day-28
Organ failure-free daysDay-7
Mortality rateUp to day-28
Duration of hospital stayUp to day-28
Percentage of patients intubatedDay-28

Countries

Rwanda

Contacts

CONTACTBruce Nzobele MUTEMBE, MD
brucemutembe@gmail.com+250783874050
CONTACTJean-Paul RWABIHAMA, MD, PhD
jeanpaulrwabihama@gmail.com+250780859127
STUDY_DIRECTORArmand Dessap MEKONSTO, MD, PhD

University of Paris-Est Cretel

STUDY_DIRECTORJean Paul RWABIHAMA, MD,PhD

University of Rwanda

STUDY_CHAIRSabin Nsanzimana, MD, PhD

Ministry of Health, Rwanda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026